In the past I have made the mistake of selling out of bio tech stocks too early.
You have to give these companies some time to develop through their trial phases. April - June 2022 are the dates tipped for Phase 2b clinical trial results.
Phase 2 we are testing the efficacy...hopefully to see if the benefits outweigh the risks. If it is positive then share price should get a rerate and we will likely need to raise more capital to progress to phase 3.
Wolf
IPO - Hexima Limited, page-28
Add HXL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.004M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500000 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 450000 | 1 |
View Market Depth
| Last trade - 16.12pm 19/07/2024 (20 minute delay) ? |
| HXL (ASX) Chart |
Day chart unavailable